Newsroom | 12856 results

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its second quarter 2026 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Second Quarter 2026 Financial Highlights Net revenues were $196.6 million, an increase of 28.8% year over year, primarily...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim...

WATERLOO, Iowa--(BUSINESS WIRE)--HOMELINK®, a leading provider of integrated specialty services for the workers’ compensation and group health industries, is pleased to welcome Anthony Jauregui and Dave Tickner to its national account management team. Both bring extensive experience in workers’ compensation, managed care, client service, and strategic account leadership. Jauregui joins HOMELINK as a national account manager and currently manages five accounts. He has extensive experience managi...

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr...

RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical Surgical unveils meaning and vision of new name, branding, as part of planned separation; expects to transition to new name in 2027....

BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TYO 6523), has launched its fifth annual This Is Diabetes Art & Photography Competition in support of World Diabetes Day 2026. This year's global competition is themed "This Is the Moment Everything Changed", inviting people from around the world to share original artwork or photography inspired by the defining moments that shape life with diabetes. For som...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor, whi...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to bec...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period Adjusted diluted EPS fr...

NORWALK, Calif.--(BUSINESS WIRE)--Universal Orthodontic Lab announced today that Dr. Ryo Hamanaka, Chief Clinical Officer and Head of the Experimental Applications Group, has been invited by the Association for the Board of Aligner Orthodontics to present at the ABAO Forum 2026. Dr. Hamanaka will discuss his contribution to the multiple-choice, computer-based knowledge examination component of ABAO’s clear aligner certification process. Drawing on his own clinical, academic, and technical exper...